ClinicalTrials.Veeva

Menu

Comparison Between Raloxifene and Bazedoxifene

T

Toshihiko Kono

Status

Unknown

Conditions

Selective Estrogen Receptor Modulator

Study type

Observational

Funder types

Other

Identifiers

NCT01973738
IRB TH 05

Details and patient eligibility

About

Although there are two kinds of selective estrogen receptor modulator (SERM) :raloxifene (RLX) and bazedoxifene (BZA), the difference is still unclear. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.

Full description

Selective estrogen receptor modulator (SERM) is an important option for postmenopausal osteoporosis. There are two SERM approved in Japan for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. One is raloxifene (RLX), and the other is bazedoxifene (BZA). There are few reports concerning to the clinical efficacy and safety data. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.

The main objective of this study is to reveal the effects of RLX and BZA on bone mineral density, bone turnover markers, and bone quality markers.

Enrollment

300 estimated patients

Sex

Female

Ages

45 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Postmenopausal women

Exclusion criteria

  • Patients who could not use SERM

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems